Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.64 |
| ▸ | MAOA | P21397 | 7/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.51 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.51 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.51 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.51 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.51 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.51 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.51 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359896 | 0.89 | MAOA (0.69) | ESR2MAOAEGFRATP1A1ATP1B1 | |
| SCHEMBL26779741 | 0.82 | MAOA (0.61) | ESR2MAOAEGFRATP1A1ATP1B1 | |
| SCHEMBL7987277 | 0.81 | ESR2 (0.70) | ESR2MAOAATP1A1ATP1B1ATP1A3 | |
| SCHEMBL8074166 | 0.81 | ESR2 (0.60) | ESR2MAOAEGFRNPSR1RXFP1 | |
| SCHEMBL5141096 | 0.80 | ATP1A1 (0.59) | MAOAEGFRATP1A1ATP1B1ATP1A3 | |
| SCHEMBL30880452 | 0.80 | ESR2 (0.57) | ESR2MAOANPSR1RXFP1LMNA | |
| SCHEMBL8492619 | 0.80 | ATP1A1 (0.56) | ESR2MAOAEGFRATP1A1ATP1B1 | |
| SCHEMBL10789961 | 0.78 | ESR2 (0.53) | ESR2MAOAEGFRATP1A1ATP1B1 | |
| SCHEMBL6825266 | 0.78 | ESR2 (1.00) | ESR2MAOA | |
| SCHEMBL29853705 | 0.78 | ESR2 (0.66) | ESR2MAOANPSR1RXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | ESR2 4060/4885MAOA 699/4885EGFR 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.